lly glp 1 drug Eli Lilly (LLY): GLP-1 Dominance, AI Discovery Novo, Lilly weight-loss drugs should
Description
Developed by Altimmune
Front Pharmacol 2022;13:925377.ArticlePubMedPMC 55
This Gs-biased profile may contribute to sustained receptor signaling with less desensitization, though the clinical implications of signaling bias in GLP-1 therapeutics remain an area of active investigation
& Malagelada, J
